Anti Amyloid Kisunla denied for failing step therapy by Humana?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Anti Amyloid Kisunla
## Why Humana Applied Step Therapy to Kisunla — and Why It May Not Apply Here
Step therapy — sometimes called "fail-first" — requires a patient to try and fail one or more alternative treatments before the plan will cover the requested drug. For Kisunla (donanemab), a step-therapy denial is particularly worth challenging because Kisunla targets a specific pathological mechanism (amyloid removal) for which there is no therapeutic equivalent in most step-therapy sequences. A drug that treats symptoms is not a clinical substitute for a drug that addresses the underlying amyloid pathology.
## Why This Denial Happens
Humana's formulary management system may apply a step-therapy protocol that was designed for symptomatic Alzheimer's medications and then mechanically extended to amyloid-targeting biologics. If the required step-therapy drugs treat different aspects of Alzheimer's disease than Kisunla does, the step-therapy requirement is not clinically appropriate and can be appealed on medical-necessity and mechanism-of-action grounds.
## Federal Protections Against Step Therapy
Many states have enacted step-therapy reform laws that require insurers to grant exceptions when step therapy is clinically inappropriate. Check whether your state's law applies to your plan type. Regardless of state law:
- Internal appeal (ACA §2719 / ERISA §503): File a written appeal arguing that the required step drugs are not therapeutically interchangeable with Kisunla and that imposing the step would cause clinically meaningful delay.
- Expedited appeal: If your neurologist certifies that delay poses a serious health risk, request expedited review (72-hour response for Humana).
- External review: After internal denial, you have approximately four months to request independent external review. IROs routinely overturn step-therapy denials when the clinical record shows the step drugs address a different mechanism or when the patient has a contraindication to the step drug per the prescribing label.
## Documentation to Gather
1. Diagnosis and staging records — Notes confirming early symptomatic Alzheimer's disease with amyloid confirmation (PET or CSF). 2. Mechanism-distinction letter — Ask the prescribing neurologist to explain in writing why the step drugs Humana requires are not clinically equivalent to Kisunla, referencing the respective FDA-approved indications and mechanisms. 3. Prior treatment history — If the patient has already tried symptomatic Alzheimer's therapies, document dates, doses as prescribed, duration, and outcomes. If those trials satisfy the step, state that explicitly. 4. Step-therapy exception criteria — Review Humana's published step-therapy exception policy and the applicable state law; document how the patient's case meets the exception criteria. 5. Humana's coverage policy for Kisunla — Obtain the current version and identify precisely which step drugs are required.
## Criteria-Mapping Structure for Your Appeal
| Step-Therapy Requirement | Humana Policy | Why It Does Not Apply or Has Been Satisfied | |---|---|---| | Required step drug(s) tried | Per Humana policy | List of prior trials with dates and outcomes (if applicable) | | Clinical equivalence claim | Humana's assertion | Neurologist letter distinguishing mechanisms | | Exception criteria met | Per Humana exception policy | Specific chart evidence for each exception ground |
State clearly in your appeal letter that Kisunla's amyloid-clearing mechanism is not replicated by any drug in Humana's step sequence, and that requiring a therapeutic trial of a non-equivalent drug introduces clinically unjustifiable delay.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →